Pharmaceutical News and Articles

New Lyme Disease Vaccine Shows Strong Results in Trial

TUESDAY, March 24, 2026 A new vaccine meant to prevent Lyme disease may be one step closer to approval. Drugmaker Pfizer and French vaccine company Valneva said

TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts

TUESDAY, March 24, 2026 TrumpRx, the president s discount program for prescription drugs, is adding three more products to its site as it continues efforts to l

High Cancer Mortality Burden Shifted From Urban to Rural Areas

From 1969 to 2023, there was a shift in the highest all-cancer mortality rates from large metropolitan areas to nonmetropolitan areas with the smallest urban po

Risk of Heat-Linked Emergency Department Use May Start at Lower Temperatures

Health care systems can leverage electronic health record data to optimize health-based heat warning interventions, according to a study published online March

Higher Maternal UPF Intake Linked to Smaller Early Embryonic Growth

Higher maternal ultraprocessed food (UPF) intake is associated with smaller early embryonic growth and yolk sac volume, while higher paternal UPF intake is asso

AHA: Cutting a Few Minutes of Sedentary Time Reduces Teens’ Risk for Insulin Resistance

Shifting even a few minutes from being sedentary to either sleep or moderate-to-vigorous physical activity (MVPA) reduces insulin resistance in teens, according

AHA: High Blood Pressure in Young Adulthood Tied to Higher Risk for Cardiovascular Events in Midlife

Higher cumulative blood pressure (BP) in young adulthood is associated with increased risks for cardiovascular disease (CVD) and kidney events in midlife, accor

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate PF-07307405 (LB6V) Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Pfizer Inc. (NYSE PFE) and Valneva SE (Nasdaq VALN Euronext Paris VLA) today announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor R

Ionis Announces Zilganersen New Drug Application for Alexander Disease (AxD) Accepted by FDA for Priority Review

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. Approval for Opdivo (nivolumab)